Roche to make upfront cash payment of $750 million for rights to Sarepta’s experimental DMD gene therapy SRP-9001 https://www.firstwordpharma.com/node/1689490  $RHHBY $SRPT

From BioPortfolio: Roche to make upfront cash payment of $750 million for rights to Sarepta’s experimental DMD gene therapy SRP-9001 https://www.firstwordpharma.com/node/1689490&a…

Read the full article here

Related Articles